TR200102699T2 - Treatment of chronic joint disorder (osteoarthritis) - Google Patents

Treatment of chronic joint disorder (osteoarthritis)

Info

Publication number
TR200102699T2
TR200102699T2 TR2001/02699T TR200102699T TR200102699T2 TR 200102699 T2 TR200102699 T2 TR 200102699T2 TR 2001/02699 T TR2001/02699 T TR 2001/02699T TR 200102699 T TR200102699 T TR 200102699T TR 200102699 T2 TR200102699 T2 TR 200102699T2
Authority
TR
Turkey
Prior art keywords
treatment
osteoarthritis
joint disorder
chronic joint
chronic
Prior art date
Application number
TR2001/02699T
Other languages
Turkish (tr)
Inventor
M. Mendel Carl
B. Seaton Timothy
P.Weinstein Steve
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of TR200102699T2 publication Critical patent/TR200102699T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

R1 ve R2 nin birbirinden baG ms z olarak H veya metil olduGu formül I'in bir bileçimi veya bunlar n farmasötik olarak kabul edilen tuzlar (örneGin, seçime baGl olarak monohidrat yap s nda N,N-dimetil-1-[1-(4-klorofenil)sislobütil]-3-metilbütil amin hidroklorit)oseteoarthritis veya gut hastal G n n tedavisi için kullan l r.R1 and R2 are H or methyl independently of each other, a combination of formula I or pharmaceutically acceptable salts thereof (e.g. N, N-dimethyl-1- [1- (4 in the structure of monohydrate depending on choice). -chlorophenyl) cyslobutyl] -3-methylbutyl amine hydrochloride) used for the treatment of oseteoarthritis or gout disease.

TR2001/02699T 1999-03-19 2000-03-17 Treatment of chronic joint disorder (osteoarthritis) TR200102699T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12530099P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
TR200102699T2 true TR200102699T2 (en) 2002-03-21

Family

ID=22419072

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02699T TR200102699T2 (en) 1999-03-19 2000-03-17 Treatment of chronic joint disorder (osteoarthritis)

Country Status (20)

Country Link
EP (1) EP1169027A4 (en)
JP (2) JP2002539248A (en)
KR (1) KR20020038567A (en)
CN (1) CN1352552A (en)
AU (1) AU773490B2 (en)
BG (1) BG105999A (en)
BR (1) BR0009081A (en)
CA (1) CA2366660A1 (en)
CZ (1) CZ20013284A3 (en)
HK (1) HK1044702A1 (en)
HU (1) HUP0200494A2 (en)
IL (1) IL145238A0 (en)
MX (1) MXPA01009461A (en)
NO (1) NO20014477L (en)
NZ (1) NZ514016A (en)
PL (1) PL365463A1 (en)
SK (1) SK13342001A3 (en)
TR (1) TR200102699T2 (en)
WO (1) WO2000056306A1 (en)
ZA (1) ZA200107682B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine.
EP0708639A4 (en) * 1992-06-23 1997-08-20 Sepracor Inc Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
JP3862295B2 (en) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 Anti-obesity agent
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
MA24500A1 (en) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd CARBOXYLIC ACID SALT DERIVATIVE FROM NAPHTHYRIDINE.

Also Published As

Publication number Publication date
HK1044702A1 (en) 2002-11-01
ZA200107682B (en) 2003-06-18
CZ20013284A3 (en) 2002-10-16
NO20014477D0 (en) 2001-09-14
JP2012051904A (en) 2012-03-15
WO2000056306A1 (en) 2000-09-28
IL145238A0 (en) 2002-06-30
JP2002539248A (en) 2002-11-19
AU773490B2 (en) 2004-05-27
CN1352552A (en) 2002-06-05
NZ514016A (en) 2001-09-28
BR0009081A (en) 2003-03-05
HUP0200494A2 (en) 2002-08-28
KR20020038567A (en) 2002-05-23
PL365463A1 (en) 2005-01-10
SK13342001A3 (en) 2002-04-04
EP1169027A1 (en) 2002-01-09
AU3893200A (en) 2000-10-09
CA2366660A1 (en) 2000-09-28
NO20014477L (en) 2001-11-01
MXPA01009461A (en) 2004-03-19
BG105999A (en) 2002-06-28
EP1169027A4 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
NO2015009I1 (en) Nintedanib, tautomers and salts thereof, in particular Nintedanib and physiologically acceptable salts thereof, in particular Nintedanib esilate; 3-Z- [1- (4- (N - ((4-methylpiperazin-1-yl) -methylcarbonyl) -N-methylamino) -anilino) -1-phenylmethylene] -6-methoxycarbonyl-2-indolinone - See among other claims 1, 2, 5 (t) and 6 of the basic patent
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
NO2010006I1 (en) Saxagliptin and pharmaceutically acceptable salts thereof including Saxagliptin hydrochloride
DK1250328T3 (en) Dihydro-1,3,5-triazine amine derivatives and their therapeutic use
RU2000119792A (en) MONOSULPHATE AZEPEPTIDA DERIVATIVE AND CONTAINING ITS PHARMACEUTICAL COMPOSITION INHIBITING HIV PROTEASIS
LU92366I2 (en) Teriflunomide, its stereoisomer and pharmaceutically acceptable salts
MXPA03008215A (en) INHIBITORS OF INTEGRIN agr;v.
TR200002605T2 (en) Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
DK1230236T3 (en) Compound with growth hormone releasing properties
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
TR200002481T2 (en) 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists
DK1379508T3 (en) N- (aryl) -2arylethenesulfonamides and therapeutic uses thereof
TR200102699T2 (en) Treatment of chronic joint disorder (osteoarthritis)
WO2000056315A8 (en) Treatment of pain
PT1226122E (en) VASOPRESSIN BICYCLING AGONISTS
TW200510370A (en) Urea derivatives
MXPA01009469A (en) Treatment to lower platelet adhesiveness.
DK0629615T3 (en) Indole derivatives as glutamate antagonists
MXPA01009468A (en) Treatment of pulmonary hypertension.
TR200102700T2 (en) Treatment of abdominal hernia (hiatal hernia).
GB2135997B (en) N-(m-trifluoromethylphenyl)-n'-propargylpiperazine
MXPA01009465A (en) Weight loss after pregnancy.
AR038847A1 (en) USE OF COMPOUND N- (3,5-DICLORO-2-METOXI-PHENYL) -4-METOXI-3-PIPERAZIN-1-IL-BENCENOSULFONAMIDE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION AND SUCH PHARMACEUTICAL COMPOSITION
TR200102692T2 (en) Treatment of certain cancers associated with weight gain
RU99116574A (en) AMINO ACID DERIVATIVES, MANIFESTING ANTI-ARITHMIC ACTIVITY